Fangchen Lin, Tung-hao Chang, Chia-chun Huang, L. Hung, T. Chou, Jhen-Bin Lin
Sorafenib-induced radiation recall dermatitis (RRD) is rare. Here we present a case of sorafenib- induced RRD previously irradiated for bone metastasis from hepatocellular carcinoma (HCC). The patient was an 86-year-old Taiwanese woman. Radiotherapy with 3,000 cGy in 10 fractions was delivered for her bone metastasis in palliative intention. A month after completion of irradiation, sorafenib 400 mg was administered orally twice daily. Pruritus occurred on the same day of initiated sorafenib, restricted to the previous irradiated skin, which progressed, one week after, to grade 1 pruritus, erythema, desquamation and hyperpigmentation of lower back without pain. (CTCAE v4.03) Topical steroid cream was prescribed without sorafenib adjustment. Her skin reaction resolved in several days later. To the best of our knowledge, this is the first case report of a female patient presenting sorafenib-triggered RRD. Our case report highlights the possibility in both genders and could provide more information for further understanding given its rarity. Clinicians should be alert to the possibility of RRD in patients with dermatologic reaction in previously irradiated skin after receiving sorafenib.
{"title":"Sorafenib-triggered radiation recall dermatitis: case report and literature review","authors":"Fangchen Lin, Tung-hao Chang, Chia-chun Huang, L. Hung, T. Chou, Jhen-Bin Lin","doi":"10.21037/tro.2019.11.01","DOIUrl":"https://doi.org/10.21037/tro.2019.11.01","url":null,"abstract":"Sorafenib-induced radiation recall dermatitis (RRD) is rare. Here we present a case of sorafenib- induced RRD previously irradiated for bone metastasis from hepatocellular carcinoma (HCC). The patient was an 86-year-old Taiwanese woman. Radiotherapy with 3,000 cGy in 10 fractions was delivered for her bone metastasis in palliative intention. A month after completion of irradiation, sorafenib 400 mg was administered orally twice daily. Pruritus occurred on the same day of initiated sorafenib, restricted to the previous irradiated skin, which progressed, one week after, to grade 1 pruritus, erythema, desquamation and hyperpigmentation of lower back without pain. (CTCAE v4.03) Topical steroid cream was prescribed without sorafenib adjustment. Her skin reaction resolved in several days later. To the best of our knowledge, this is the first case report of a female patient presenting sorafenib-triggered RRD. Our case report highlights the possibility in both genders and could provide more information for further understanding given its rarity. Clinicians should be alert to the possibility of RRD in patients with dermatologic reaction in previously irradiated skin after receiving sorafenib.","PeriodicalId":93236,"journal":{"name":"Therapeutic radiology and oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/tro.2019.11.01","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45373015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Martini, Giuseppe Carlo Iorio, F. Arcadipane, U. Ricardi, P. Franco
The number of new cases of rectal cancer (RC) estimated per year is across 704,000 worldwide. Approximately 310,000 death cases are reported per year among RC patients, globally (1). Roughly 20% of patients with RC present with metastatic disease and their prognosis depends on the extent of tumor burden (2).
{"title":"The importance of loco-regional control in metastatic rectal cancer","authors":"S. Martini, Giuseppe Carlo Iorio, F. Arcadipane, U. Ricardi, P. Franco","doi":"10.21037/TRO.2019.05.04","DOIUrl":"https://doi.org/10.21037/TRO.2019.05.04","url":null,"abstract":"The number of new cases of rectal cancer (RC) estimated per year is across 704,000 worldwide. Approximately 310,000 death cases are reported per year among RC patients, globally (1). Roughly 20% of patients with RC present with metastatic disease and their prognosis depends on the extent of tumor burden (2).","PeriodicalId":93236,"journal":{"name":"Therapeutic radiology and oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/TRO.2019.05.04","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47967160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-05-01Epub Date: 2019-05-24DOI: 10.21037/tro.2019.05.01
Aadel A Chaudhuri, Kevin Chen, Maximilian Diehn, Billy W Loo
Stereotactic ablative radiotherapy (SABR) has emerged as a standard-of-care treatment for patients with early stage non-small cell lung cancer (NSCLC) who are poor surgical candidates. Current evidence supports the consensus that lung SABR with BED ≥100 Gy leads to high local tumor control, and that the treatment is generally well-tolerated when applied to peripheral lung tumors. However, several studies present conflicting evidence for the treatment of central and ultra-central lung tumors, with some showing superb outcomes and others showing concerning rates of morbidity and mortality. Therefore, treatment of central and especially ultra-central lung tumors with SABR remains controversial. In this review, we aim to present the existing evidence for SABR treatment of central and ultra-central lung tumors and delineate the factors that could lead to significant toxicity.
{"title":"Stereotactic Ablative Radiotherapy for Central and Ultra-Central Lung Tumors.","authors":"Aadel A Chaudhuri, Kevin Chen, Maximilian Diehn, Billy W Loo","doi":"10.21037/tro.2019.05.01","DOIUrl":"https://doi.org/10.21037/tro.2019.05.01","url":null,"abstract":"<p><p>Stereotactic ablative radiotherapy (SABR) has emerged as a standard-of-care treatment for patients with early stage non-small cell lung cancer (NSCLC) who are poor surgical candidates. Current evidence supports the consensus that lung SABR with BED ≥100 Gy leads to high local tumor control, and that the treatment is generally well-tolerated when applied to peripheral lung tumors. However, several studies present conflicting evidence for the treatment of central and ultra-central lung tumors, with some showing superb outcomes and others showing concerning rates of morbidity and mortality. Therefore, treatment of central and especially ultra-central lung tumors with SABR remains controversial. In this review, we aim to present the existing evidence for SABR treatment of central and ultra-central lung tumors and delineate the factors that could lead to significant toxicity.</p>","PeriodicalId":93236,"journal":{"name":"Therapeutic radiology and oncology","volume":"3 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/tro.2019.05.01","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38814880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lung stereotactic ablative radiotherapy (SABR) is almost invariably associated with radiation-induced parenchymal injury within 3 years of treatment completion. While distinguishing normal fibrotic changes from local recurrence is challenging, accurate detection of local relapse has become increasingly crucial in the context of rapidly growing SABR patients’ population and multiplying salvage therapy options. Knowledge of the natural history of radiation-induced lung injury as well as recognition of the risk factors associated with recurrence are essential to assist timely diagnosis of recurrence while avoiding unnecessary investigations. In this review, we discuss the patterns of recurrence after SABR, the expected post-treatment radiological changes as well as the prevailing and evolving strategies to differentiate recurrence from radiation-induced lung injury. The limitations of the current response assessment methods and the promising avenues of functional imaging and radiomics are discussed. Finally, current general consensus guidelines for surveillance post-SABR for early-stage non-small cell lung cancer are summarized.
{"title":"Response assessment and surveillance following stereotactic ablative radiotherapy for lung cancer","authors":"D. Mathieu, H. Bahig","doi":"10.21037/TRO.2019.03.05","DOIUrl":"https://doi.org/10.21037/TRO.2019.03.05","url":null,"abstract":"Lung stereotactic ablative radiotherapy (SABR) is almost invariably associated with radiation-induced parenchymal injury within 3 years of treatment completion. While distinguishing normal fibrotic changes from local recurrence is challenging, accurate detection of local relapse has become increasingly crucial in the context of rapidly growing SABR patients’ population and multiplying salvage therapy options. Knowledge of the natural history of radiation-induced lung injury as well as recognition of the risk factors associated with recurrence are essential to assist timely diagnosis of recurrence while avoiding unnecessary investigations. In this review, we discuss the patterns of recurrence after SABR, the expected post-treatment radiological changes as well as the prevailing and evolving strategies to differentiate recurrence from radiation-induced lung injury. The limitations of the current response assessment methods and the promising avenues of functional imaging and radiomics are discussed. Finally, current general consensus guidelines for surveillance post-SABR for early-stage non-small cell lung cancer are summarized.","PeriodicalId":93236,"journal":{"name":"Therapeutic radiology and oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47394972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
X. Chen, J. White, Wenhui Li, E. Ahunbay, A. Currey, C. Bergom, T. Kelly, J. Wilson, X. Li
Background: The purpose of this study is to quantitatively characterize interfraction variations of lumpectomy cavity (LC) in accelerated partial breast irradiation (APBI) and their dosimetric impacts, and to explore the use of an online adaptive replanning scheme to address these variations. Methods: A total of about 100 diagnostic-quality CT sets acquired using an in-room CT at each fraction during image-guided radiation therapy (IGRT) for ten randomly-selected patients treated with APBI in the supine position were analyzed. The LC, treated breast, lung and heart were delineated on each fraction CT. Organ volume change and deformation were quantified. For each fraction CT, three types of plans were created: adaptive, repositioning, and fully re-optimized plans. The plan qualities were compared. Results: Significant changes in LC shape and volume were observed during APBI. On average, the LC volume decreases by 23% from the planning CT. The average change in LC shape, as measured by the Dice’s coefficient, is 80%. For all patients, the adaptive plans were comparable to the re-optimization plans. For small and moderate LC changes (70%), the three types of plans were comparable, indicating that the current IGRT with the standard margins was sufficient to account for the interfraction variations. For cases with extreme LC change (30%), the adaptive plans offered improved target coverage and/or normal tissue sparing as compared with the repositioning plans. Conclusions: Significant variations in the LC between planning and treatment were found for APBI. The current practice of IGRT with standard planning target volume margins can account for these variations for most cases. Online adaptive replanning was needed for cases with extremely large changes in LC.
{"title":"Assessment and management of interfraction variations of lumpectomy cavities in accelerated partial breast irradiation","authors":"X. Chen, J. White, Wenhui Li, E. Ahunbay, A. Currey, C. Bergom, T. Kelly, J. Wilson, X. Li","doi":"10.21037/TRO.2019.03.04","DOIUrl":"https://doi.org/10.21037/TRO.2019.03.04","url":null,"abstract":"Background: The purpose of this study is to quantitatively characterize interfraction variations of lumpectomy cavity (LC) in accelerated partial breast irradiation (APBI) and their dosimetric impacts, and to explore the use of an online adaptive replanning scheme to address these variations. \u0000 Methods: A total of about 100 diagnostic-quality CT sets acquired using an in-room CT at each fraction during image-guided radiation therapy (IGRT) for ten randomly-selected patients treated with APBI in the supine position were analyzed. The LC, treated breast, lung and heart were delineated on each fraction CT. Organ volume change and deformation were quantified. For each fraction CT, three types of plans were created: adaptive, repositioning, and fully re-optimized plans. The plan qualities were compared. Results: Significant changes in LC shape and volume were observed during APBI. On average, the LC volume decreases by 23% from the planning CT. The average change in LC shape, as measured by the Dice’s coefficient, is 80%. For all patients, the adaptive plans were comparable to the re-optimization plans. For small and moderate LC changes (70%), the three types of plans were comparable, indicating that the current IGRT with the standard margins was sufficient to account for the interfraction variations. For cases with extreme LC change (30%), the adaptive plans offered improved target coverage and/or normal tissue sparing as compared with the repositioning plans. \u0000 Conclusions: Significant variations in the LC between planning and treatment were found for APBI. The current practice of IGRT with standard planning target volume margins can account for these variations for most cases. Online adaptive replanning was needed for cases with extremely large changes in LC.","PeriodicalId":93236,"journal":{"name":"Therapeutic radiology and oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/TRO.2019.03.04","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45215311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Stereotactic body radiotherapy (SBRT) is a highly dose-concentrated radiotherapy that can spare damage to normal organs much more than conventional radiotherapy. Severe radiation pneumonitis (RP) after stereotactic SBRT for thoracic lesions is rare but sometimes gets severe. In this review, we presented the reported frequency of severe RP after SBRT for stage I NSCLC, its risk factors, and the attempts at clarifying individual predictive risk factors. The ratio of fatal RP after SBRT for lung tumor in patients with accompanying pulmonary interstitial changes is more than 5%, and overall survival is poor. The dose to the normal lung and interstitial changes in the background lung are important predictive factors of severe RP, with idiopathic pulmonary fibrosis (IPF) being the biggest risk factor for severe RP, but these interstitial lung diseases (ILDs) are not always a contraindication for thoracic SBRT. Based on the high fatality rate, it would be reasonable to avoid prompt SBRT by watchful waiting in cases of indolent or non-aggressive tumors, such as ground-glass tumors. It would be better to use or recommend more highly precise irradiation systems or particle therapy (PT) that can reduce radiation doses to the normal lung more, in particular for the cases with IPF. Identification of biomarkers indicating an individual’s risk level for severe RP, such as single nucleotide polymorphisms (SNPs), would be important in treatment decisions, but it needs further research. Though there are no reliable drugs for treating severe RP, anti-fibrotic agents, such as pirfenidone, might be effective in its prevention or alleviation.
{"title":"Stereotactic body radiotherapy for lung cancer in patients with interstitial lung disease","authors":"H. Onishi","doi":"10.21037/TRO.2019.03.03","DOIUrl":"https://doi.org/10.21037/TRO.2019.03.03","url":null,"abstract":"Stereotactic body radiotherapy (SBRT) is a highly dose-concentrated radiotherapy that can spare damage to normal organs much more than conventional radiotherapy. Severe radiation pneumonitis (RP) after stereotactic SBRT for thoracic lesions is rare but sometimes gets severe. In this review, we presented the reported frequency of severe RP after SBRT for stage I NSCLC, its risk factors, and the attempts at clarifying individual predictive risk factors. The ratio of fatal RP after SBRT for lung tumor in patients with accompanying pulmonary interstitial changes is more than 5%, and overall survival is poor. The dose to the normal lung and interstitial changes in the background lung are important predictive factors of severe RP, with idiopathic pulmonary fibrosis (IPF) being the biggest risk factor for severe RP, but these interstitial lung diseases (ILDs) are not always a contraindication for thoracic SBRT. Based on the high fatality rate, it would be reasonable to avoid prompt SBRT by watchful waiting in cases of indolent or non-aggressive tumors, such as ground-glass tumors. It would be better to use or recommend more highly precise irradiation systems or particle therapy (PT) that can reduce radiation doses to the normal lung more, in particular for the cases with IPF. Identification of biomarkers indicating an individual’s risk level for severe RP, such as single nucleotide polymorphisms (SNPs), would be important in treatment decisions, but it needs further research. Though there are no reliable drugs for treating severe RP, anti-fibrotic agents, such as pirfenidone, might be effective in its prevention or alleviation.","PeriodicalId":93236,"journal":{"name":"Therapeutic radiology and oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/TRO.2019.03.03","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41841420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The role of prophylactic cranial irradiation (PCI) for extensive-stage small-cell lung cancer (ES-SCLC) has evolved since the publication of two phase III randomized control trials in the past decade. Despite significant evidence demonstrating improvements in survival and rates of developing brain metastasis in the limited-stage setting, there was no clear evidence supporting its use for ES-SCLC until 2007, with the publication of the European Organization for Research and Treatment of Cancer (EORTC) study.
{"title":"What is the role of prophylactic cranial irradiation for extensive-stage small-cell lung cancer in an evolving field?","authors":"A. Bang, R. MacRae","doi":"10.21037/TRO.2019.03.01","DOIUrl":"https://doi.org/10.21037/TRO.2019.03.01","url":null,"abstract":"The role of prophylactic cranial irradiation (PCI) for extensive-stage small-cell lung cancer (ES-SCLC) has evolved since the publication of two phase III randomized control trials in the past decade. Despite significant evidence demonstrating improvements in survival and rates of developing brain metastasis in the limited-stage setting, there was no clear evidence supporting its use for ES-SCLC until 2007, with the publication of the European Organization for Research and Treatment of Cancer (EORTC) study.","PeriodicalId":93236,"journal":{"name":"Therapeutic radiology and oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/TRO.2019.03.01","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49187952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The 18 th International Congress on Neutron Capture Therapy (ICNCT) was successfully held in Taipei, Taiwan from October 28 to November 2. Researchers came from different countries, such as Japan, USA, Italy, Argentina, Germany, Finland, etc. to attend this grand meeting. The gathering of researchers in the fields of radiology, chemistry, physics, nuclear medicine and pathology has enriched and stimulated discussion during the meeting.
{"title":"Interview with Prof. Hiroshi Fukuda: the 50-year history of boron neutron capture therapy","authors":"Wei-En Fan","doi":"10.21037/TRO.2019.02.03","DOIUrl":"https://doi.org/10.21037/TRO.2019.02.03","url":null,"abstract":"The 18 th International Congress on Neutron Capture Therapy (ICNCT) was successfully held in Taipei, Taiwan from October 28 to November 2. Researchers came from different countries, such as Japan, USA, Italy, Argentina, Germany, Finland, etc. to attend this grand meeting. The gathering of researchers in the fields of radiology, chemistry, physics, nuclear medicine and pathology has enriched and stimulated discussion during the meeting.","PeriodicalId":93236,"journal":{"name":"Therapeutic radiology and oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/TRO.2019.02.03","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47295571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mastectomy or breast conserving surgery (BCS) followed by adjuvant radiotherapy (RT) and/or chemotherapy plus hormone therapy is the current standard of care for breast cancer (BC). The disease usually progresses in patients who refuse any form of surgical intervention and notoriously impacts their life expectancy and quality. We collected 5 BC patients who refused any form of surgery and who received definitive RT or RT with chemotherapy (CCRT). The staging included early stage to locally advanced BCs according to criteria of the American Joint Committee on Cancer (AJCC) version 7. All patients achieved good local control. Only one had recurrence and was successfully salvaged by re-irradiation. The cosmetic effects were all satisfactory. Primary CCRT for BC patients who refuse surgery can be an effective alternative for achieving good survival and maintaining good quality of life.
{"title":"Primary chemo-radiotherapy for breast cancer patients who refused surgical treatment: a case series","authors":"P. Kao, M. Chi, K. Chi, H. Ko","doi":"10.21037/TRO.2019.05.05","DOIUrl":"https://doi.org/10.21037/TRO.2019.05.05","url":null,"abstract":"Mastectomy or breast conserving surgery (BCS) followed by adjuvant radiotherapy (RT) and/or chemotherapy plus hormone therapy is the current standard of care for breast cancer (BC). The disease usually progresses in patients who refuse any form of surgical intervention and notoriously impacts their life expectancy and quality. We collected 5 BC patients who refused any form of surgery and who received definitive RT or RT with chemotherapy (CCRT). The staging included early stage to locally advanced BCs according to criteria of the American Joint Committee on Cancer (AJCC) version 7. All patients achieved good local control. Only one had recurrence and was successfully salvaged by re-irradiation. The cosmetic effects were all satisfactory. Primary CCRT for BC patients who refuse surgery can be an effective alternative for achieving good survival and maintaining good quality of life.","PeriodicalId":93236,"journal":{"name":"Therapeutic radiology and oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/TRO.2019.05.05","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43909675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In the Red Journal , Lukka and colleagues reported optimal quality of life (QoL) outcomes of the NRG Oncology RTOG 0938 trial (1). This trial randomly compared two short radiation schedules of 5 and 12 fractions of 7.25 and 4.3 Gy each, respectively, for the treatment of localized, low risk prostate cancer. The primary endpoint was the proportion of patients with a change in bowel and urinary EPIC-50 score at 1-year.
{"title":"Quality of life after ultra-hypofractionated radiotherapy for prostate cancer: the challenge of RTOG 0938 trial","authors":"S. Arcangeli, V. Pinzi","doi":"10.21037/tro.2019.02.01","DOIUrl":"https://doi.org/10.21037/tro.2019.02.01","url":null,"abstract":"In the Red Journal , Lukka and colleagues reported optimal quality of life (QoL) outcomes of the NRG Oncology RTOG 0938 trial (1). This trial randomly compared two short radiation schedules of 5 and 12 fractions of 7.25 and 4.3 Gy each, respectively, for the treatment of localized, low risk prostate cancer. The primary endpoint was the proportion of patients with a change in bowel and urinary EPIC-50 score at 1-year.","PeriodicalId":93236,"journal":{"name":"Therapeutic radiology and oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/tro.2019.02.01","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44179634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：